Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Using specific immunoradiometric assays, we evaluated the clinical usefulness of chromogranin A and the alpha-subunit of glycoprotein hormones in neuroendocrine tumours of neuroectodermic origin. The serum alpha-subunit of glycoprotein hormones was only slightly increased in 2 out of 44 medullary thyroid carcinoma or phaeochromocytoma patients with increased calcitonin or 24-hour urinary metanephrine levels. Serum chromogranin A was increased in 12 of 45 (27%) medullary thyroid carcinoma patients with an elevated calcitonin level and in 4 of 16 medullary thyroid carcinoma patients (25%) with an undetectable calcitonin level, in 5 of 7 phaeochromocytoma patients with increased urinary catecholamine and metabolite excretion, and in 2 of 3 patients with a non-functioning phaeochromocytoma. During follow-up, the course of chromogranin A was found to parallel that of tumour burden and/or 24-hour urinary metanephrine in 5 phaeochromocytoma patients. We conclude that chromogranin A measurement is not recommended for the diagnosis of medullary thyroid carcinoma patients. It may be useful in patients with functioning and non-functioning phaeochromocytomas as a follow-up marker. In neuroendocrine tumour patients with elevated calcitonin secretion, the serum alpha-subunit of glycoprotein hormone measurement may help differentiate medullary thyroid carcinoma or phaeochromocytoma patients from other endodermal-derived neuroendocrine tumour patients in whom it is frequently elevated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sanduleanu, Stridsberg, Jonkers, Hameeteman, Biemond, Lundqvist, Lamers, & Stockbrügger (1999) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1999.00466.x · Cited by 111
Cited by
Valkema, R., de Jong, M., Bakker, W. H., Breeman, W. A. P., Kooij, P. P. M., Lugtenburg, P. J., de Jong, F. H., Christiansen, A., Kam, B. L. R., de Herder, W. W., et al. (2002) · Seminars in Nuclear Medicine · doi:10.1053/snuc/2002.31025 · Cited by 435
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
The diagnosis and management of malignant phaeochromocytoma and paraganglioma
Chrisoulidou, A., Kaltsas, G., Ilias, I., & Grossman, A. B. (2007) · Endocrine-Related Cancer · doi:10.1677/erc-07-0074 · Cited by 314
Leboulleux, S., Baudin, E., Travagli, J., & Schlumberger, M. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02037.x · Cited by 281
Self-citationChromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Metadata
- Authors
- Guignat, L., Bidart, J. M., Nocera, M., Comoy, E., Schlumberger, M., & Baudin, E.
- Venue
- British Journal of Cancer
- Published
- 2001
- Volume
- 84
- Issue
- 6
- Pages
- 808-812
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2023417364
- Cited by
- 49
- References
- 1
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. https://app.cochat.ai/papers/10.1054/bjoc.2000.1677
- The paper
- Guignat, L., Bidart, J. M., Nocera, M., Comoy, E., Schlumberger, M., & Baudin, E. (2001). Chromogranin A and the α -subunit of glycoprotein hormones in medullary thyroid carcinoma and phaeochromocytoma. British Journal of Cancer. https://doi.org/10.1054/bjoc.2000.1677
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.